Biosimilar comparator

Reference biologics and their FDA-licensed biosimilars (FDA Purple Book), with Medicare Part B payment limits for Q4 2026. Payment differences are not therapeutic guidance — interchangeability and substitution follow FDA licensure and state law.

Switch simulator

Annual effect of moving part of a reference product’s volume to a biosimilar, from the CMS payment limit per mg. Costs you enter stay in this browser.

Reference productSwitch to

Doses / yearmg / dose

Share switched: 50%

Add your acquisition cost per mg (optional)

Eylea (J0178) $/mgPavblu (Q5147) $/mg

Annual totals before and after the switch
Annual	All Eylea	50% switched	Change
Medicare allowed	$60,669,084	$62,396,334	+$1,727,250
Patient coinsurance (all patients)	$12,133,817	$12,479,267	+$345,450
Expected revenue (after sequestration)	$59,698,379	$61,397,993	+$1,699,614
Your acquisition cost	—	—	—
Margin	—	—	—

84,000 mg a year · Eylea (J0178): $722.2510/mg · Pavblu (Q5147): $763.3760/mg. Per-dose coinsurance changes by $5,758 for a switched patient. Annual-mg arithmetic: rounding of each dose to whole billing units is not modeled. Switching decisions follow clinical judgment, FDA interchangeability, and state law.

aflibercept — Eylea

Reference product: Eylea. 1 biosimilar product linked by the reference BLA in the Purple Book.

Dose (mg, optional)

Enter a dose to compare the Medicare allowed amount and the patient’s coinsurance.

Payment comparison for aflibercept
Product	HCPCS	Limit / unit	Per mg	CMS methodology
EyleaReference product	J0178	$722.251per 1 MG	$722.2510	ASP methodology (per CMS file)
PavbluBiosimilar	Q5147	$763.376per 1 MG	$763.3760+5.7% vs reference	ASP methodology (per CMS file)

bevacizumab — Avastin

Reference product: Avastin. 5 biosimilar products linked by the reference BLA in the Purple Book.

Dose (mg, optional)

Enter a dose to compare the Medicare allowed amount and the patient’s coinsurance.

Payment comparison for bevacizumab
Product	HCPCS	Limit / unit	Per mg	CMS methodology
VegzelmaBiosimilar	Q5129	$21.139per 10 MG	$2.1139−72% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
ZirabevBiosimilar	Q5118	$25.939per 10 MG	$2.5939−65.6% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
MvasiBiosimilar	Q5107	$28.294per 10 MG	$2.8294−62.5% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
AvastinReference product	J9035	$75.492per 10 MG	$7.5492	ASP methodology (per CMS file)
AlymsysBiosimilar	Q5126	$79.982per 10 MG	$7.9982+5.9% vs reference	ASP methodology (per CMS file)
JobevneBiosimilar	Q5160	$82.139per 10 MG	$8.2139+8.8% vs reference	ASP methodology (per CMS file)

denosumab — Prolia

Reference product: Prolia. 6 biosimilar products linked by the reference BLA in the Purple Book.

Dose (mg, optional)

Enter a dose to compare the Medicare allowed amount and the patient’s coinsurance.

Payment comparison for denosumab
Product	HCPCS	Limit / unit	Per mg	CMS methodology
EnobyInterchangeable biosimilar	Q5167	$7.681per 1 MG	$7.6810−74.3% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
BildyosInterchangeable biosimilar	Q5162	$15.336per 1 MG	$15.3360−48.6% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
StobocloInterchangeable biosimilar	Q5157	$24.002per 1 MG	$24.0020−19.6% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
JubbontiInterchangeable biosimilar	Q5136	$26.991per 1 MG	$26.9910−9.6% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
BosayaInterchangeable biosimilar	Q5161	$27.509per 1 MG	$27.5090−7.9% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
ConexxenceInterchangeable biosimilar	Q5158	$28.702per 1 MG	$28.7020−3.9% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
ProliaReference product	J0897	$29.856per 1 MG	$29.8560	ASP methodology (per CMS file)

denosumab — Xgeva

Reference product: Xgeva. 6 biosimilar products linked by the reference BLA in the Purple Book.

Dose (mg, optional)

Enter a dose to compare the Medicare allowed amount and the patient’s coinsurance.

Payment comparison for denosumab
Product	HCPCS	Limit / unit	Per mg	CMS methodology
XtrenboInterchangeable biosimilar	Q5167	$7.681per 1 MG	$7.6810−74.3% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
BilprevdaInterchangeable biosimilar	Q5162	$15.336per 1 MG	$15.3360−48.6% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
OsenveltInterchangeable biosimilar	Q5157	$24.002per 1 MG	$24.0020−19.6% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
WyostInterchangeable biosimilar	Q5136	$26.991per 1 MG	$26.9910−9.6% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
AukelsoInterchangeable biosimilar	Q5161	$27.509per 1 MG	$27.5090−7.9% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
BomyntraInterchangeable biosimilar	Q5158	$28.702per 1 MG	$28.7020−3.9% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
XgevaReference product	J0897	$29.856per 1 MG	$29.8560	ASP methodology (per CMS file)

eculizumab — Soliris

Reference product: Soliris. 2 biosimilar products linked by the reference BLA in the Purple Book.

Dose (mg, optional)

Enter a dose to compare the Medicare allowed amount and the patient’s coinsurance.

Payment comparison for eculizumab
Product	HCPCS	Limit / unit	Per mg	CMS methodology
EpysqliInterchangeable biosimilar	Q5151	$31.547per 2 MG	$15.7735−27.9% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
BkemvInterchangeable biosimilar	Q5152	$40.412per 2 MG	$20.2060−7.7% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
SolirisReference product	J1299	$43.763per 2 MG	$21.8815	ASP methodology (per CMS file)

erythropoietin — Procrit

Reference product: Procrit. 1 biosimilar product linked by the reference BLA in the Purple Book.

Dose (mg, optional)

Enter a dose to compare the Medicare allowed amount and the patient’s coinsurance.

Payment comparison for erythropoietin
Product	HCPCS	Limit / unit	Per units	CMS methodology
ProcritReference product	J0885	$6.669per 1000 UNITS	$0.0067	ASP methodology (per CMS file)
ProcritReference product	Q4081	$0.667per 100 UNITS	$0.0067+0% vs reference	ASP methodology (per CMS file)
RetacritBiosimilar	Q5105	$0.817per 100 UNITS	$0.0082+22.5% vs reference	ASP methodology (per CMS file)
RetacritBiosimilar	Q5106	$8.171per 1000 UNITS	$0.0082+22.5% vs reference	ASP methodology (per CMS file)

filgrastim — Neupogen

Reference product: Neupogen. 6 biosimilar products linked by the reference BLA in the Purple Book.

Dose (mg, optional)

Enter a dose to compare the Medicare allowed amount and the patient’s coinsurance.

Payment comparison for filgrastim
Product	HCPCS	Limit / unit	Per mcg	CMS methodology
ReleukoBiosimilar	Q5125	$0.308per 1 MCG	$0.3080−69% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
NivestymBiosimilar	Q5110	$0.329per 1 MCG	$0.3290−66.9% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
ZarxioBiosimilar	Q5101	$0.338per 1 MCG	$0.3380−66% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
NeupogenReference product	J1442	$0.994per 1 MCG	$0.9940	ASP methodology (per CMS file)
NYPOZI txidBiosimilar	Q5148	$1.026per 1 MCG	$1.0260+3.2% vs reference	ASP methodology (per CMS file)
NypoziBiosimilar	Q5148	$1.026per 1 MCG	$1.0260+3.2% vs reference	ASP methodology (per CMS file)

infliximab — Remicade

Reference product: Remicade. 3 biosimilar products linked by the reference BLA in the Purple Book.

Dose (mg, optional)

Enter a dose to compare the Medicare allowed amount and the patient’s coinsurance.

Payment comparison for infliximab
Product	HCPCS	Limit / unit	Per mg	CMS methodology
RenflexisBiosimilar	Q5104	$25.649per 10 MG	$2.5649−14.1% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
InflectraBiosimilar	Q5103	$28.456per 10 MG	$2.8456−4.7% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
RemicadeReference product	J1745	$29.856per 10 MG	$2.9856	ASP methodology (per CMS file)
AvsolaBiosimilar	Q5121	$34.686per 10 MG	$3.4686+16.2% vs reference	ASP methodology (per CMS file)

natalizumab — Tysabri

Reference product: Tysabri. 1 biosimilar product linked by the reference BLA in the Purple Book.

Dose (mg, optional)

Enter a dose to compare the Medicare allowed amount and the patient’s coinsurance.

Payment comparison for natalizumab
Product	HCPCS	Limit / unit	Per mg	CMS methodology
TysabriReference product	J2323	$23.927per 1 MG	$23.9270	ASP methodology (per CMS file)
TyrukoBiosimilar	Q5134	$24.397per 1 MG	$24.3970+2% vs reference	ASP methodology (per CMS file)

pegfilgrastim — Neulasta

Reference product: Neulasta. 7 biosimilar products linked by the reference BLA in the Purple Book.

Dose (mg, optional)

Enter a dose to compare the Medicare allowed amount and the patient’s coinsurance.

Payment comparison for pegfilgrastim
Product	HCPCS	Limit / unit	Per mg	CMS methodology
FulphilaBiosimilar	Q5108	$55.964per 0.5 MG	$111.9280−72.2% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
FylnetraBiosimilar	Q5130	$94.292per 0.5 MG	$188.5840−53.1% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
UdenycaBiosimilar	Q5111	$128.967per 0.5 MG	$257.9340−35.9% vs reference	AMP-based payment limit (per CMS note)
NyvepriaBiosimilar	Q5122	$141.289per 0.5 MG	$282.5780−29.8% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
StimufendBiosimilar	Q5127	$163.948per 0.5 MG	$327.8960−18.5% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
NeulastaReference product	J2506	$201.241per 0.5 MG	$402.4820	ASP methodology (per CMS file)
ZiextenzoBiosimilar	Q5120	$302.247per 0.5 MG	$604.4940+50.2% vs reference	ASP methodology (per CMS file)
ArmlupegBiosimilar	Q5169	$519.481per 0.5 MG	$1,038.9620+158.1% vs reference	ASP methodology (per CMS file)

ranibizumab — Lucentis

Reference product: Lucentis. 3 biosimilar products linked by the reference BLA in the Purple Book.

Dose (mg, optional)

Enter a dose to compare the Medicare allowed amount and the patient’s coinsurance.

Payment comparison for ranibizumab
Product	HCPCS	Limit / unit	Per mg	CMS methodology
LucentisReference product	J2778	$26.384per 0.1 mg	$263.8400	ASP methodology (per CMS file)
NufymcoInterchangeable biosimilar	Q5168	$26.384per 0.1 MG	$263.8400−0% vs reference	ASP methodology (per CMS file)
CimerliInterchangeable biosimilar	Q5128	$81.130per 0.1 MG	$811.3000+207.5% vs reference	ASP methodology (per CMS file)
ByoovizInterchangeable biosimilar	Q5124	$249.493per 0.1 MG	$2,494.9300+845.6% vs reference	ASP methodology (per CMS file)

rituximab — Rituxan

Reference product: Rituxan. 3 biosimilar products linked by the reference BLA in the Purple Book.

Dose (mg, optional)

Enter a dose to compare the Medicare allowed amount and the patient’s coinsurance.

Payment comparison for rituximab
Product	HCPCS	Limit / unit	Per mg	CMS methodology
RuxienceBiosimilar	Q5119	$5.792per 10 MG	$0.5792−92% vs reference	AMP-based payment limit (per CMS note)
RiabniBiosimilar	Q5123	$21.083per 10 MG	$2.1083−70.8% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
TruximaInterchangeable biosimilar	Q5115	$35.988per 10 MG	$3.5988−50.1% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
RituxanReference product	J9312	$72.094per 10 MG	$7.2094	ASP methodology (per CMS file)

tocilizumab — Actemra

Reference product: Actemra. 3 biosimilar products linked by the reference BLA in the Purple Book.

Dose (mg, optional)

Enter a dose to compare the Medicare allowed amount and the patient’s coinsurance.

Payment comparison for tocilizumab
Product	HCPCS	Limit / unit	Per mg	CMS methodology
AvtozmaInterchangeable biosimilar	Q5156	$3.098per 1 MG	$3.0980−41.8% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
TyenneBiosimilar	Q5135	$4.370per 1 MG	$4.3700−17.9% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
TofidenceBiosimilar	Q5133	$4.706per 1 MG	$4.7060−11.6% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
AvtozmaInterchangeable biosimilar	Q0237	$4.920per 1 MG	$4.9200−7.6% vs reference	95% of AWP (vaccine; per CMS file)
ActemraReference product	J3262	$5.325per 1 MG	$5.3250	ASP methodology (per CMS file)
TyenneBiosimilar	Q0238	$5.581per 1 MG	$5.5810+4.8% vs reference	95% of AWP (vaccine; per CMS file)
TofidenceBiosimilar	Q0234	$6.327per 1 MG	$6.3270+18.8% vs reference	95% of AWP (vaccine; per CMS file)
ActemraReference product	Q0249	$7.569per 1 MG	$7.5690+42.1% vs reference	95% of AWP (vaccine; per CMS file)

trastuzumab — Herceptin

Reference product: Herceptin. 9 biosimilar products linked by the reference BLA in the Purple Book.

Dose (mg, optional)

Enter a dose to compare the Medicare allowed amount and the patient’s coinsurance.

Payment comparison for trastuzumab
Product	HCPCS	Limit / unit	Per mg	CMS methodology
TrazimeraBiosimilar	Q5116	$11.271per 10 MG	$1.1271−83.6% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
OgivriBiosimilar	Q5114	$29.507per 10 MG	$2.9507−57.2% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
OgivriBiosimilar	Q5114	$29.507per 10 MG	$2.9507−57.2% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
HercessiBiosimilar	Q5146	$30.255per 10 MG	$3.0255−56.1% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
OntruzantBiosimilar	Q5112	$32.791per 10 MG	$3.2791−52.4% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
OntruzantBiosimilar	Q5112	$32.791per 10 MG	$3.2791−52.4% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
OntruzantBiosimilar	Q5112	$32.791per 10 MG	$3.2791−52.4% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
HerzumaBiosimilar	Q5113	$55.295per 10 MG	$5.5295−19.7% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
KanjintiBiosimilar	Q5117	$63.871per 10 MG	$6.3871−7.3% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
HerceptinReference product	J9355	$68.871per 10 MG	$6.8871	ASP methodology (per CMS file)

ustekinumab — Stelara

Reference product: Stelara. 10 biosimilar products linked by the reference BLA in the Purple Book.

Dose (mg, optional)

Enter a dose to compare the Medicare allowed amount and the patient’s coinsurance.

Payment comparison for ustekinumab
Product	HCPCS	Limit / unit	Per mg	CMS methodology
WezlanaInterchangeable biosimilar	Q5138	$2.273per 1 MG	$2.2730−77.8% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
SteqeymaInterchangeable biosimilar	Q5099	$2.890per 1 MG	$2.8900−71.8% vs reference	“Lesser of” methodology applied (per CMS note)
YesintekInterchangeable biosimilar	Q5100	$3.080per 1 MG	$3.0800−69.9% vs reference	“Lesser of” methodology applied (per CMS note)
PyzchivaInterchangeable biosimilar	Q9997	$8.591per 1 MG	$8.5910−16.2% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
Ustekinumab-ttweInterchangeable biosimilar	Q9997	$8.591per 1 MG	$8.5910−16.2% vs reference	Biosimilar: 8% of reference product add-on applied (per CMS note)
ImuldosaInterchangeable biosimilar	Q5098	$9.270per 1 MG	$9.2700−9.6% vs reference	“Lesser of” methodology applied (per CMS note)
StelaraReference product	J3358	$10.249per 1 MG	$10.2490	ASP methodology (per CMS file)
SelarsdiInterchangeable biosimilar	Q9998	$10.480per 1 MG	$10.4800+2.3% vs reference	“Lesser of” methodology applied (per CMS note)
Ustekinumab-aeknInterchangeable biosimilar	Q9998	$10.480per 1 MG	$10.4800+2.3% vs reference	“Lesser of” methodology applied (per CMS note)
OtulfiInterchangeable biosimilar	Q9999	$13.246per 1 MG	$13.2460+29.2% vs reference	“Lesser of” methodology applied (per CMS note)
Ustekinumab-aauzInterchangeable biosimilar	Q9999	$13.246per 1 MG	$13.2460+29.2% vs reference	“Lesser of” methodology applied (per CMS note)

“Per mg” divides the CMS payment limit by the billing unit in the CMS dosage column. Allowed amount = whole billing units for the dose × the payment limit; patient coinsurance uses the percentage in the CMS file. Derived arithmetic, before deductible and sequestration.

Disclaimer. This application provides informational coding and reimbursement reference data. It does not constitute legal, clinical, coding, or billing advice. Codes, payment amounts, payer rules, and coverage policies can change. Verify all information with current CMS publications, the applicable payer, and your organization’s compliance policies before submitting a claim. CodeRx is not affiliated with or endorsed by CMS, FDA, Medicare, or any payer.